IRIS
PERSONENI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.333
AS - Asia 2.587
EU - Europa 874
SA - Sud America 430
AF - Africa 106
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 5
Totale 8.343
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.217
SG - Singapore 1.531
CN - Cina 505
BR - Brasile 354
VN - Vietnam 208
FI - Finlandia 178
IT - Italia 153
IE - Irlanda 110
DE - Germania 98
HK - Hong Kong 79
CA - Canada 77
NG - Nigeria 65
IN - India 64
GB - Regno Unito 59
NL - Olanda 54
FR - Francia 52
BD - Bangladesh 40
SE - Svezia 40
AR - Argentina 28
JP - Giappone 25
BE - Belgio 21
MX - Messico 21
TR - Turchia 21
IQ - Iraq 18
RU - Federazione Russa 17
PL - Polonia 16
CL - Cile 14
EC - Ecuador 14
CZ - Repubblica Ceca 12
UZ - Uzbekistan 12
ES - Italia 11
PK - Pakistan 10
AT - Austria 9
CO - Colombia 9
EG - Egitto 9
IL - Israele 9
ZA - Sudafrica 9
ID - Indonesia 8
UA - Ucraina 8
AE - Emirati Arabi Uniti 7
SA - Arabia Saudita 7
IR - Iran 6
KE - Kenya 6
PT - Portogallo 6
AZ - Azerbaigian 5
EU - Europa 5
KR - Corea 5
MA - Marocco 5
AU - Australia 4
BG - Bulgaria 4
ET - Etiopia 4
JM - Giamaica 4
MY - Malesia 4
NP - Nepal 4
PE - Perù 4
PH - Filippine 4
VE - Venezuela 4
BA - Bosnia-Erzegovina 3
DO - Repubblica Dominicana 3
HN - Honduras 3
KG - Kirghizistan 3
LT - Lituania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AF - Afghanistan, Repubblica islamica di 2
BY - Bielorussia 2
DK - Danimarca 2
DZ - Algeria 2
HR - Croazia 2
HU - Ungheria 2
LB - Libano 2
MD - Moldavia 2
NI - Nicaragua 2
NO - Norvegia 2
PY - Paraguay 2
RO - Romania 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AL - Albania 1
AO - Angola 1
BH - Bahrain 1
CG - Congo 1
CH - Svizzera 1
CR - Costa Rica 1
DM - Dominica 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
IM - Isola di Man 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MM - Myanmar 1
MN - Mongolia 1
PA - Panama 1
PS - Palestinian Territory 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TV - Tuvalu 1
Totale 8.341
Salva come PNG Salva come JPEG
Città #
Singapore 682
Dallas 658
Chandler 516
Wilmington 409
Ashburn 329
San Jose 203
The Dalles 199
Shanghai 182
Helsinki 177
San Mateo 162
Beijing 142
Ann Arbor 131
New York 112
Dublin 109
Boardman 97
Lawrence 82
Princeton 82
Ho Chi Minh City 80
Leawood 77
Benin City 64
Hong Kong 59
Milan 53
Amsterdam 48
Los Angeles 48
Santa Clara 45
Hanoi 44
Paris 40
Phoenix 38
Woodbridge 30
Seattle 28
São Paulo 27
Toronto 27
London 26
Buffalo 24
Fairfield 22
Montreal 20
Pune 20
Brussels 18
Orem 16
Warsaw 16
San Diego 15
Munich 14
Haiphong 12
Rio de Janeiro 12
Brooklyn 11
Porto Alegre 10
Tashkent 10
Baghdad 9
Chennai 9
Chicago 9
Kocaeli 9
Naples 9
Tokyo 9
Abbiategrasso 8
Assago 8
Dhaka 8
Frankfurt am Main 8
San Francisco 8
Andover 7
Atlanta 7
Council Bluffs 7
Da Nang 7
Norwalk 7
Salvador 7
Belo Horizonte 6
Brasília 6
Brno 6
Cairo 6
Falkenstein 6
Guayaquil 6
Istanbul 6
Jeddah 6
Monmouth Junction 6
Raleigh 6
Redwood City 6
Biên Hòa 5
Bogotá 5
Charlotte 5
Chengdu 5
Columbus 5
Curitiba 5
Denver 5
Johannesburg 5
Manchester 5
Mexico City 5
Nairobi 5
Phủ Lý 5
Redmond 5
Ribeirão Preto 5
Rome 5
Umeda 5
Boston 4
Canoas 4
Falls Church 4
Houston 4
Hải Dương 4
Jersey City 4
Ludhiana 4
Mumbai 4
Porto 4
Totale 5.544
Salva come PNG Salva come JPEG
Nome #
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients 163
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 141
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 128
Tivantinib for hepatocellular carcinoma 120
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 118
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 116
Biomarkers in Hepatocellular Carcinoma-Letter 110
COVID-19 and liver cancer clinical trials: not everything is lost 108
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 107
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 106
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 106
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 105
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 105
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 104
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 103
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 100
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 98
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 98
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 96
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 94
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma 94
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 92
Cabozantinib for the treatment of hepatocellular carcinoma 90
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 90
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study 89
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 88
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 86
Shaping the landscape of immune oncology in hepatocellular carcinoma 86
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 86
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 86
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 86
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 85
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 85
Reply to Y. Pointreau et al 84
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 83
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date 83
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine 83
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 83
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 83
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 83
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 83
KRAS mutation in lung metastases from colorectal cancer : Prognostic implications 82
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 81
Role of liver biopsy in hepatocellular carcinoma 81
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 80
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 79
Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study 79
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial. 78
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 78
Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial 77
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 76
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study 75
Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications 75
Targeted agents for second-line treatment of advanced hepatocellular carcinoma 74
Regorafenib for the treatment of unresectable hepatocellular carcinoma 74
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. 74
Tumour burden score and immune???related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors 73
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC 73
The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients 73
Hepatocellular carcinoma: a global disease in need of individualized treatment strategies 72
Sorafenib in hepatitis C-virus negative patients with hepatocellular carcinoma: don’t throw the baby out with the bathwater 72
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 71
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomized, placebo-controlled phase 2 study. 70
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 70
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? 70
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials 70
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 69
SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS 68
Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer single institution experience 67
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score 66
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study 66
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 66
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 65
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 64
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 64
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 63
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade 61
Gauging the quality-of-life benefits of immunotherapy in hepatocellular carcinoma 61
Exploring novel avenues for neoadjuvant treatment of hepatocellular carcinoma 61
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives 61
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND) 60
Rationale for immunotherapy combination strategies in unresectable hepatocellular carcinoma 60
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 59
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 59
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy 59
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 58
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 58
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 57
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study 56
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer 56
The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges 55
Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma 55
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 54
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 54
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice 52
The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials 52
Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipes 51
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma 51
Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients 51
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 50
Totale 7.920
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.588
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.588
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202186 0 0 0 0 0 0 0 0 0 0 0 86
2021/2022553 15 8 2 105 16 14 24 80 64 104 82 39
2022/20231.466 194 81 136 188 147 118 13 113 230 104 114 28
2023/2024939 72 77 170 50 35 145 82 34 9 15 104 146
2024/20251.205 46 22 3 29 33 128 120 108 200 244 117 155
2025/20263.569 492 668 176 314 80 157 869 130 175 199 171 138
Totale 8.501